schliessen

Filtern

 

Bibliotheken

Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.

A randomised controlled trial was conducted in 29 HBV carriers who had been HBs and HBe antigen positive for more than six months. Fifteen patients were treated with ARA-AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days. The 14 contro... Full description

Journal Title: Gut 1 July 1985, Vol.26(7), p.745
Main Author: Weller, I V
Other Authors: Lok, A S , Mindel, A , Karayiannis, P , Galpin, S , Monjardino, J , Sherlock, S , Thomas, H C
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: BMJ Publishing Group Ltd and British Society of Gastroenterology
ID: ISSN: 0017-5749 ; E-ISSN: 1468-3288 ; DOI: 10.1136/gut.26.7.745 ; PMID: 2410328
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: bmj_journals10.1136/gut.26.7.745
title: Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
format: Article
creator:
  • Weller, I V
  • Lok, A S
  • Mindel, A
  • Karayiannis, P
  • Galpin, S
  • Monjardino, J
  • Sherlock, S
  • Thomas, H C
subjects:
  • Hepatitis B
ispartof: Gut, 1 July 1985, Vol.26(7), p.745
description: A randomised controlled trial was conducted in 29 HBV carriers who had been HBs and HBe antigen positive for more than six months. Fifteen patients were treated with ARA-AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days. The 14 controls received no treatment. Serum HBV-DNA polymerase, and HBV-DNA decreased in all patients during therapy. Six treated patients lost serum HBV-DNA polymerase, HBV-DNA and HBeAg, HBsAg concentrations decreased, and five developed anti-HBe. One of these six patients lost HBsAg and developed anti-HBs. No such changes were observed in the control group over a similar 18 month period of observation. A four week course of ARA-AMP inhibits HBV replication and in a significant minority of patients this is long lasting and is associated with a reduced level of inflammatory activity in the liver.
language: eng
source:
identifier: ISSN: 0017-5749 ; E-ISSN: 1468-3288 ; DOI: 10.1136/gut.26.7.745 ; PMID: 2410328
fulltext: fulltext_linktorsrc
issn:
  • 00175749
  • 14683288
  • 0017-5749
  • 1468-3288
url: Link


@attributes
ID32165534
RANK0.06999999
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1136/gut.26.7.745
sourceidbmj_journals
recordidTN_bmj_journals10.1136/gut.26.7.745
sourcesystemPC
pqid14304198
display
typearticle
titleRandomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
creatorWeller, I V ; Lok, A S ; Mindel, A ; Karayiannis, P ; Galpin, S ; Monjardino, J ; Sherlock, S ; Thomas, H C
publisherBMJ Publishing Group Ltd and British Society of Gastroenterology
ispartofGut, 1 July 1985, Vol.26(7), p.745
identifier
subjectHepatitis B
descriptionA randomised controlled trial was conducted in 29 HBV carriers who had been HBs and HBe antigen positive for more than six months. Fifteen patients were treated with ARA-AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days. The 14 controls received no treatment. Serum HBV-DNA polymerase, and HBV-DNA decreased in all patients during therapy. Six treated patients lost serum HBV-DNA polymerase, HBV-DNA and HBeAg, HBsAg concentrations decreased, and five developed anti-HBe. One of these six patients lost HBsAg and developed anti-HBs. No such changes were observed in the control group over a similar 18 month period of observation. A four week course of ARA-AMP inhibits HBV replication and in a significant minority of patients this is long lasting and is associated with a reduced level of inflammatory activity in the liver.
languageeng
source
oafree_for_read
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
linktorsrc$$Uhttp://gut.bmj.com/content/26/7/745.full.pdf$$EView_this_record_in_BMJ_Journals
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Weller, I V
1Lok, A S
2Mindel, A
3Karayiannis, P
4Galpin, S
5Monjardino, J
6Sherlock, S
7Thomas, H C
titleRandomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
descriptionA randomised controlled trial was conducted in 29 HBV carriers who had been HBs and HBe antigen positive for more than six months. Fifteen patients were treated with ARA-AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days. The 14 controls received no treatment. Serum HBV-DNA polymerase, and HBV-DNA decreased in all patients during therapy. Six treated patients lost serum HBV-DNA polymerase, HBV-DNA and HBeAg, HBsAg concentrations decreased, and five developed anti-HBe. One of these six patients lost HBsAg and developed anti-HBs. No such changes were observed in the control group over a similar 18 month period of observation. A four week course of ARA-AMP inhibits HBV replication and in a significant minority of patients this is long lasting and is associated with a reduced level of inflammatory activity in the liver.
subjectHepatitis B
general
0BMJ Publishing Group Ltd and British Society of Gastroenterology
1BMJ Journals (BMJ Publishing Group)
210.1136/gut.26.7.745
32410328
4BMJ Open Access and Free Journals (BMJ Publishing Group)
sourceidbmj_journals
recordidbmj_journals10.1136/gut.26.7.745
issn
000175749
114683288
20017-5749
31468-3288
rsrctypearticle
creationdate1985
addtitleGut
searchscope
0bmj
1bmj_oa
scope
0bmj
1bmj_oa
citationpf 745 vol 26 issue 7
startdate19850701
enddate19850701
lsr30VSR-Enriched:[pages, pqid]
sort
titleRandomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
authorWeller, I V ; Lok, A S ; Mindel, A ; Karayiannis, P ; Galpin, S ; Monjardino, J ; Sherlock, S ; Thomas, H C
creationdate19850701
lso0119850701
facets
frbrgroupid8959935080437332945
frbrtype5
creationdate1985
topicHepatitis B
collectionBMJ Open Access and Free Journals (BMJ Publishing Group)
creatorcontrib
0Weller, I V
1Lok, A S
2Mindel, A
3Karayiannis, P
4Galpin, S
5Monjardino, J
6Sherlock, S
7Thomas, H C
jtitleGut
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
aulast
0Weller
1Lok
2Mindel
3Karayiannis
4Galpin
5Monjardino
6Sherlock
7Thomas
aufirst
0I V
1A S
2A
3P
4S
5J
6H C
auinitI
au
0Weller, I V
1Lok, A S
2Mindel, A
3Karayiannis, P
4Galpin, S
5Monjardino, J
6Sherlock, S
7Thomas, H C
atitleRandomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
jtitleGut
stitleGut
risdate19850701
volume26
issue7
spage745
issn
00017-5749
100175749
eissn
01468-3288
114683288
formatjournal
abstractA randomised controlled trial was conducted in 29 HBV carriers who had been HBs and HBe antigen positive for more than six months. Fifteen patients were treated with ARA-AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days. The 14 controls received no treatment. Serum HBV-DNA polymerase, and HBV-DNA decreased in all patients during therapy. Six treated patients lost serum HBV-DNA polymerase, HBV-DNA and HBeAg, HBsAg concentrations decreased, and five developed anti-HBe. One of these six patients lost HBsAg and developed anti-HBs. No such changes were observed in the control group over a similar 18 month period of observation. A four week course of ARA-AMP inhibits HBV replication and in a significant minority of patients this is long lasting and is associated with a reduced level of inflammatory activity in the liver.
pubBMJ Publishing Group Ltd and British Society of Gastroenterology
doi10.1136/gut.26.7.745
urlhttp://gut.bmj.com/content/26/7/745.full.pdf
pmid2410328
oafree_for_read
pages745-51
date1985-07-01